Skip to main content
A federal review of Medicaid fee-for-service (FFS) claims in five states for second-generation antipsychotics (SGAs) prescribed to children ages 0 to 17 found that 92% were prescribed off-label, while only 8% were prescribed for a medically accepted pediatric indication. The review covered a sample of 687 FFS Medicaid claims for SGAs prescribed to children in California, Florida, Illinois, New York, and Texas. In 2011, these states represented 39% of total Medicaid payments for SGAs. The review found one or more quality of care concerns in 67% of claims; 49% of claims had two or more quality . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!


Support Request

Need help now?

Call our toll-free phone number 877-350-6463